AgeX Therapeutics, Inc. - News

2023 2022 2021 2020 2019 2018 2017

12/22/2020

AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

11/16/2020

AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

10/28/2020

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome

09/09/2020

AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes

08/14/2020

AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

06/16/2020

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications

06/05/2020

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

06/02/2020

AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS

05/29/2020

AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A

05/21/2020

AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer

05/14/2020

AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

05/01/2020

AgeX Therapeutics Announces Reduction in Projected Cash Expenditures

03/30/2020

AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update

03/20/2020

AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis

02/28/2020

AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells

02/03/2020

AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders

01/29/2020

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

01/14/2020

AgeX Therapeutics to Participate at Four Conferences in January 2020